{"meta":{"query_hash":"76cd4a7dbc8f","filters":{"venue":"Journal of symptoms and signs"},"cohort_total":2,"direct_labels_cover":0,"predictions_cover":2,"exported":2,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/76cd4a7dbc8f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+symptoms+and+signs"},"results":[{"id":"W1483755438","doi":"","title":"Efficacy and safety of temsirolimus in renal cell carcinoma","year":2015,"lang":"en","type":"article","venue":"Journal of symptoms and signs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Temsirolimus; Renal cell carcinoma; Medicine; Oncology; Cancer research; PI3K/AKT/mTOR pathway; Internal medicine; Cancer; Kinase; Pharmacology; Discovery and development of mTOR inhibitors; Biology; Signal transduction","score_opus":0.025357491342728664,"score_gpt":0.253109595627089,"score_spread":0.22775210428436035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1483755438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.885427,0.09776474,0.00205025,0.0011821238,0.00013737517,0.0003123722,0.0005870277,0.00008488521,0.012454143],"genre_scores_gemma":[0.9867113,0.0105327405,0.0007392828,0.0003579868,0.0000879444,0.00005645342,0.0003586867,0.0000146713,0.0011409452],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961805,0.00013470007,0.000049832848,0.000035250447,0.00013925425,0.000022888189],"domain_scores_gemma":[0.9994924,0.00017538958,0.00012093095,0.00003511728,0.00012487102,0.0000512133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008448842,0.0000931557,0.0006651592,0.00019637991,0.00012334035,0.0002495402,0.00013065763,0.00018513904,0.0010706659],"category_scores_gemma":[0.0012414663,0.000049950002,0.0004224964,0.00024401493,0.00011096403,0.00021441128,0.00009803132,0.0005861983,0.00019515856],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016570792,0.0019374399,0.025914045,0.0025899122,0.0008104331,0.00053645985,0.00019979678,0.0032618886,0.07893899,0.0008037291,0.0044009862,0.8640356],"study_design_scores_gemma":[0.009188562,0.2101932,0.34733367,0.0012846504,0.0036139206,0.010748023,0.0005168703,0.013483304,0.23804997,0.0020906203,0.16338076,0.00011653001],"about_ca_topic_score_codex":0.00070067105,"about_ca_topic_score_gemma":0.0013416404,"teacher_disagreement_score":0.0010706659,"about_ca_system_score_codex":0.0005369165,"about_ca_system_score_gemma":0.00050834107,"threshold_uncertainty_score":0.0044682026},"labels":[],"label_agreement":null},{"id":"W750040606","doi":"","title":"Ustekinumab in the treatment of psoriasis","year":2015,"lang":"en","type":"article","venue":"Journal of symptoms and signs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Medicine; Psoriatic arthritis; Psoriasis; Placebo; Randomized controlled trial; Clinical trial; Secukinumab; Dermatology; Internal medicine; Disease; Adalimumab; Pathology; Alternative medicine","score_opus":0.034403699488213695,"score_gpt":0.25994316459705097,"score_spread":0.22553946510883727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W750040606","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0086654695,0.9663262,0.00084424793,0.004879969,0.0015215569,0.000058038226,0.0001088635,0.00007878352,0.017516853],"genre_scores_gemma":[0.1513846,0.818367,0.0020261856,0.006735517,0.0037672995,0.0001306703,0.00040155085,0.000032717024,0.01715454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961084,0.00013288663,0.00004223948,0.000041460593,0.00013958724,0.000033113574],"domain_scores_gemma":[0.9997669,0.000068981426,0.000056079156,0.000011563707,0.000055420103,0.00004099514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082319,0.0003145813,0.00056923745,0.00058619154,0.00021209556,0.0004550295,0.00024392075,0.0007463152,0.0054315985],"category_scores_gemma":[0.0006068933,0.00012521064,0.00038130555,0.0006664857,0.00028830036,0.00036044433,0.00038671005,0.0023569502,0.0023273772],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012827793,0.00026086866,0.00054183253,0.0021982056,0.00007927212,0.0004956483,0.000053064483,0.00026650872,0.0059046885,0.0029157023,0.03386266,0.9521387],"study_design_scores_gemma":[0.0021246169,0.0023977363,0.00611561,0.0019955132,0.0002836748,0.0054915594,0.000068533904,0.0006262724,0.0053695603,0.0042444733,0.9712436,0.000038828344],"about_ca_topic_score_codex":0.00062745437,"about_ca_topic_score_gemma":0.0012839308,"teacher_disagreement_score":0.0054315985,"about_ca_system_score_codex":0.00044406066,"about_ca_system_score_gemma":0.00043121245,"threshold_uncertainty_score":0.018170476},"labels":[],"label_agreement":null}]}